<DOC>
	<DOC>NCT00723905</DOC>
	<brief_summary>Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.</brief_summary>
	<brief_title>Remicade Infusion Management Program</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subject is a good candidate to receive infliximab as per the Product Monograph Subject is prescribed infliximab by an appropriate physician Subject receives infusion in a community infusion centre. Subject has signed the approved consent form. Not specified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Crohn's Disease, Rheumatoid Arthritis</keyword>
</DOC>